News / Presse
Planning for new GMP production facilities
HAPILA is ramping up its production capacity with two new GMP plants now in its manufacturing pipeline. The concept design is almost complete and includes a 240 m2 area for new GMP production facilities with a capacity of up to 600 liters and the necessary filtration and drying capacities. The first new plant to come online, will expand capacity for existing products, while a second will provide the capability to manufacture additional products. Both plants are being designed to handle syntheses under GMP compliance to meet growing pharma industry demand for high quality APIs manufactured in the European Union.
The concept design, developed in partnership with Weimar based Glatt Ingenieurtechnik GmbH (GIT) is almost complete, allowing work to continue on engineering of interiors, transfer area and manufacturing facilities, to prepare detailed specifications for equipment and plant suppliers. All installation steps will be accompanied by necessary regulatory qualifications, with installation planned to start at the end of 2021, bearing in mind that longer delivery times for the equipment could be possible because of bottlenecks on supplies and materials across Europe caused by COVID-19.
Increasing our capacities will enable HAPILA to deliver higher amounts of APIs and a greater variety to provide customers for their approved drugs and for their drugs currently under development.